Diploma PLC (LON:DPLM - Get Free Report) insider Katie Bickerstaffe acquired 44 shares of the firm's stock in a transaction dated Wednesday, May 21st. The stock was bought at an average price of GBX 4,867 ($65.27) per share, for a total transaction of £2,141.48 ($2,871.77).
Katie Bickerstaffe also recently made the following trade(s):
- On Tuesday, May 20th, Katie Bickerstaffe acquired 39 shares of Diploma stock. The stock was bought at an average price of GBX 4,981 ($66.80) per share, for a total transaction of £1,942.59 ($2,605.06).
- On Tuesday, May 20th, Katie Bickerstaffe bought 13 shares of Diploma stock. The shares were acquired at an average price of GBX 4,982 ($66.81) per share, for a total transaction of £647.66 ($868.53).
Diploma Stock Performance
LON:DPLM opened at GBX 4,802 ($64.40) on Thursday. Diploma PLC has a 52 week low of GBX 3,532 ($47.36) and a 52 week high of GBX 5,025 ($67.39). The company has a fifty day simple moving average of GBX 3,967.56 and a two-hundred day simple moving average of GBX 4,257.56. The company has a quick ratio of 0.80, a current ratio of 2.17 and a debt-to-equity ratio of 62.17. The company has a market cap of £6.40 billion, a price-to-earnings ratio of 55.20, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75.
Diploma (LON:DPLM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 21st. The company reported GBX 80.20 ($1.08) earnings per share for the quarter. Diploma had a return on equity of 13.18% and a net margin of 9.25%. As a group, equities analysts anticipate that Diploma PLC will post 163.7995512 earnings per share for the current fiscal year.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
